A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma

Prosthesis Survival Clinical Trial

Official title:

A Randomized, Controlled, Double-blind Study to Evaluate Efficacy and Survival of Combining Nimotuzumab Plus Concurrent Chemo-radiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02409186
• Other study ID #: NXCEL1311
• Status: Recruiting
• Phase: Phase 3
• First received: December 3, 2014
• Last updated: April 19, 2016
• Start date: March 2015
• Est. completion date: December 2021

Study information

• Verified date: April 2016
• Source: Shandong Cancer Hospital and Institute
• Contact: Jinming Yu, Ph.D, M.D
• Phone: 13806406293
• Email: jn7984729[@]public.jn.sd.cn
• Is FDA regulated: No
• Health authority: China: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

Esophageal cancer is the sixth leading cause of cancer death in worldwide. Over the past 2 decades, well-designed clinical trials have documented the clinical benefits of combination of chemotherapy and radiation for localized esophageal cancer, either as primary therapy or in neoadjuvant setting. Paclitaxel, a radiation sensitizer, has important single-agent activity in esophageal cancer. Paclitaxel-based chemoradiation has been the framework for the recent Radiation Therapy Oncology Group (RTOG) trials of nonoperative management of esophageal cancer. Accumulating clinical evidence suggests that Epidermal Growth Factor Receptor (EGFR) represents a viable target in the treatment of esophageal cancer. EGFR expression is associated with poor prognosis. Nimotuzumab binds specifically to EGFR on both normal and tumor cells and competitively inhibits the binding of Epidermal Growth Factor (EGF) and other ligands, such as Transforming Growth Factor-α (TGF-α). Preclinical models have suggested synergy between nimotuzumab, paclitaxel, cisplatin and radiation. For our phase II study in locally advanced esophageal squamous cell carcinoma (ESCC), the combination of cetuximab and chemoradiotherapy has demonstrated both response and survival benefits. Myara et al reported that nimotuzumab plus concurrent chemoradiation therapy (CCRT) was safe and provided statistically significant objective response (47.8%) and disease control rate (60.9%) in nonresectable ESCC. With all these, the investigators plan to study phase III trial.

Description:

The primary endpoint of this study is overall survival, and the primary hypothesis is the experimental arm will improve median survival time (MST) from 18.2 month to 28.5 month. Assuming bilateral ɑ = 0.05, statistical power of 80%.Each group requires a minimum of 59 cases. Consider the 20% loss factor.The total sample size is 200 cases.It is 100 cases in each group.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: December 2021
• Est. primary completion date: December 2017
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Signed written informed consent prior to study entry

2. age:18-70 years

3. Histopathology confirmed primary esophageal squamous cell carcinoma, meet one of the following criteria (AJCC Staging System,2009,Seventh Edition):Cervical esophageal carcinoma(stage II-III);upper thoracic esophageal cancer or chest esophageal cancer that is unsuitable or refuse surgery (stage II-III)

4. The existence of measurable lesions (according to Response Evaluation Criteria in Solid Tumors 1.1)

5. Eastern Cooperative Oncology Group(ECOG)Performance status of 0-1

6. Possible semi-liquid diet

7. If there is a risk of pregnancy, male and female subjects must be effective contraception during treatment

8. Normal bone marrow reserve: neutrophil (ANC) count=1500/mm3,platelet count=100,000 /mm3, hemoglobin=5.6mmol/L(9g/dL)

9. Normal renal function: serum creatinine=1.5mg/dl and/or calculated creatinine clearance= 60ml/min

10. Normal hepatic function: bilirubin level=1.5×ULN, alanine aminotransferase aspartate transaminase(ASAT)& ALST=1.5×ULN

11. Subjects tumor tissue available for the relevant biomarker detection

Exclusion Criteria:

1. Previous chest radiotherapy, systemic chemotherapy, and major esophageal surgery

2. Concurrent chronic systemic immune therapy, targeted therapy, anti-vascular endothelial growth factor(VEGF)therapy or EGFR-pathway targeting therapy not indicated in this study protocol

3. Multiple primary carcinomas of the esophagus

4. Pregnancy (confirmed by urine ß-HCG) or lactation period

5. Uncontrolled diabetes, hypertension, and severe cardiac or pulmonary disease

6. There are obvious esophageal ulcers, chest and back more than moderate pain, symptoms of esophageal perforation

7. Unable to comprehend the study requirements or who are not likely to comply with the study requirements

8. Patients with distant metastasis

9. Patients with other malignant disease, except for curable non-melanoma skin cancer, cervical carcinoma in situ or malignant disease cure for=5 years

10. Known grade 3 or 4 allergic reaction to any of the study treatment

11. Peripheral neuropathy > grade 1

12. Participation in another clinical study within the past 30 days

13. Significant disease which, in the investigator's opinion, would exclude the patient from the study

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma, Squamous Cell
• Esophageal Neoplasms
• Prosthesis Survival

Intervention

Drug:
• Nimotuzumab
400mg/w,d1, week 1-7

Radiation:
• radiotherapy
Three dimensional conformal RT(3DCRT)/IntensityModulatedRadiationTherapy(IMRT):1.8 Gy/f/day, T59.4 Gy/33f,week 1-7

Drug:
• chemoradiotherapy Paclitaxel
45 mg/m2, d1, week 1-7
• chemoradiotherapy Cisplatin
20 mg/m2, d1, week 1-7

Other:
• placebo
400mg/w,d1, week 1-7

Locations

Country	Name	City	State
China	Beijing Cancer Hospital	Beijing	Beijing
China	Cancer Hospital Chinese Academy of Medical Sciences	Beijing	Beijing
China	The First Hospital of Zhejiang Province	Hangzhou	Zhejiang
China	Zhejiang Cancer Hospital	Hangzhou	Zhejiang
China	Shandong Cancer Hospital and Institute	Jinan	Shandong
China	Jiangsu Cancer Hospital	Nanjing	Jiangsu
China	The Guangxi Zhuang Autonomous Region Cancer Hospita	Nanning	Guangxi
China	Renji Hospital Shanghai Jiao Tong University School of Medicine	Shanghai	Shanghai
China	Cancer Hospital of Shantou University Medical College	Shantou	Guangdong
China	The First Hospital of China Medical University	Shenyang	Liaoning
China	Fourth Hospital of Hebei Medical University Tumor	Shijiazhuang	Hebei
China	Henan Cancer Hospital	Zhengzhou	Henan
China	Affiliated Hospital of Jiangsu University	Zhenjiang	Jiangsu
China	Affiliated Hospital of Zunyi Medical College	Zunyi	Guizhou

Sponsors (1)

Lead Sponsor	Collaborator
Shandong Cancer Hospital and Institute

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Over Survival		up to 5 years	Yes